PT - JOURNAL ARTICLE AU - Elavarasi, Arunmozhimaran AU - Prasad, Manya AU - Seth, Tulika AU - Sahoo, Ranjit Kumar AU - Madan, Karan AU - Nischal, Neeraj AU - Soneja, Manish AU - Sharma, Atul AU - Maulik, Subir Kumar AU - Shalimar, AU - Garg, Pramod TI - Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis AID - 10.1101/2020.07.04.20146381 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.04.20146381 4099 - http://medrxiv.org/content/early/2020/07/06/2020.07.04.20146381.short 4100 - http://medrxiv.org/content/early/2020/07/06/2020.07.04.20146381.full AB - Background There is no effective therapy for COVID-19. Hydroxychloroquine (HCQ) and chloroquine (CQ) have been used for its treatment but their safety and efficacy remain uncertain.Objective We performed a systematic review to synthesize the available data on the efficacy and safety of CQ and HCQ for the treatment of COVID-19.Methods Two reviewers searched for published and pre-published relevant articles between December 2019 to 8th June 2020. The data from the selected studies were abstracted and analyzed for efficacy and safety outcomes. Critical appraisal of the evidence was done by Cochrane risk of bias tool and Newcastle Ottawa scale. The quality of evidence was graded as per the GRADE approach.Results We reviewed 12 observational and 3 randomized trials which included 10659 patients of whom 5713 received CQ/HCQ and 4966 received only standard of care. The efficacy of CQ/HCQ for COVID-19 was inconsistent across the studies. Meta-analysis of included studies revealed no significant reduction in mortality with HCQ use [RR 0.98 95% CI 0.66-1.46], time to fever resolution [mean difference −0.54 days (-1.19-011)] or clinical deterioration/development of ARDS with HCQ [RR 0.90 95% CI 0.47-1.71]. There was a higher risk of ECG abnormalities/arrhythmia with HCQ/CQ [RR 1.46 95% CI 1.04 to 2.06]. The quality of evidence was graded as very low for these outcomes.Author’s Conclusion The available evidence suggests that CQ or HCQ does not improve clinical outcomes in COVID-19. Well-designed randomized trials are required for assessing the efficacy and safety of HCQ and CQ for COVID-19..Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe present study is a systematic review and meta-analysisFunding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Present study is a systematic review and meta-analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe present study is a systematic review and meta-analysis